TARS - NASDAQ

Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc.

TARSยทNASDAQ

$58.76

-0.29%
HealthcareBiotechnology

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$2.53B
EPS-1.5900
P/E Ratio-36.96
Earnings Date08/05/2026
Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc. Fair Value Envelope

TARS ยท NASDAQ

Our analysis suggests that TARS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $58.76, this represents a potential HIDDEN relative to our calculated worth for Tarsus Pharmaceuticals, Inc..

HIDDEN
Intrinsic Value
Current Price: $58.76

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$4.4B
+ Cash & Equivalents$183.6M
Firm Value-$4.2B
- Debt$93.6M
Equity Value-$4.3B
/ Shares Outstanding42,449,105B
DCF Value-$101
OVERVALUED BY 271%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$21.6M
-$37.5M
-$65.2M
-$113.2M
-$196.5M
-$341.1M
-$592.3M
-$1.0B
-$1.8B
-$3.1B
Maintenance CapEx
-$3.4M
-$5.9M
-$10.3M
-$17.9M
-$31.1M
-$54.0M
-$93.8M
-$162.9M
-$282.8M
-$490.9M
Owner Earnings
-$25.0M
-$43.5M
-$75.5M
-$131.1M
-$227.6M
-$395.1M
-$686.1M
-$1.2B
-$2.1B
-$3.6B
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$23.2M
-$37.3M
-$59.9M
-$96.3M
-$154.9M
-$249.0M
-$400.3M
-$643.6M
-$1.0B
-$1.7B
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your TARS research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.